Candel Therapeutics Inc

자세한 내용은 Candel Therapeutics Inc 회사

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

회사 정보

종목 코드 CADL

회사 이름Candel Therapeutics Inc

상장일Jul 27, 2021

CEODr. Paul Peter Tak, M.D., Ph.D.

직원 수38

유형Ordinary Share

회계 연도 종료Jul 27

주소117 Kendrick Street,

도시NEEDHAM

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호02494

전화16179165445

웹사이트https://www.candeltx.com/

종목 코드 CADL

상장일Jul 27, 2021

CEODr. Paul Peter Tak, M.D., Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Christopher (Chris) Martell

Independent Director

435.51K

--

Dr. Paul Peter Tak, M.D., Ph.D.

President, Chief Executive Officer, Director

268.57K

+18.97%

Dr. Francesca Barone, M.D., Ph.D.

Chief Scientific Officer

100.81K

+4.44%

Mr. Charles Schoch

Chief Financial Officer

43.39K

+14.07%

Mr. Joseph C. (Joe) Papa

Independent Director

38.03K

--

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00K

--

Dr. Edward J. Benz, Jr., M.D.

Independent Director

--

Ms. Seshu Tyagarajan, Ph.D.

Chief Technical and Development Officer

--

Mr. Paul B. Manning

Independent Chairman of the Board

--

Dr. W. Garrett Nichols, M.D.

Chief Medical Officer

--

이름

이름/직위

직위

주식 보유

변동

Mr. Christopher (Chris) Martell

Independent Director

435.51K

--

Dr. Paul Peter Tak, M.D., Ph.D.

President, Chief Executive Officer, Director

268.57K

+18.97%

Dr. Francesca Barone, M.D., Ph.D.

Chief Scientific Officer

100.81K

+4.44%

Mr. Charles Schoch

Chief Financial Officer

43.39K

+14.07%

Mr. Joseph C. (Joe) Papa

Independent Director

38.03K

--

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00K

--

수익 분석

FY2024

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q3

데이터 없음

지역별USD

이름

수익

비율

United States

0.00

0.00%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 24

주주

주주 유형

주주

비율

Fidelity Management & Research Company LLC

13.50%

Manning (Paul B.)

5.38%

Acorn Capital Advisors, LLC

4.92%

Baker Bros. Advisors LP

4.64%

Aguilar-Cordova (Estuardo)

4.61%

Other

66.94%

주주

비율

Fidelity Management & Research Company LLC

13.50%

Manning (Paul B.)

5.38%

Acorn Capital Advisors, LLC

4.92%

Baker Bros. Advisors LP

4.64%

Aguilar-Cordova (Estuardo)

4.61%

Other

66.94%

주주 유형

주주

비율

Investment Advisor

29.01%

Individual Investor

16.48%

Investment Advisor/Hedge Fund

6.21%

Hedge Fund

5.99%

Corporation

2.48%

Research Firm

0.64%

Bank and Trust

0.09%

Pension Fund

0.02%

Insurance Company

0.02%

Other

39.06%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

162

31.98M

60.95%

-104.17K

2025Q1

160

30.10M

67.51%

-1.81M

2024Q4

131

27.38M

62.24%

+9.09M

2024Q3

115

17.10M

48.26%

-703.44K

2024Q2

98

16.89M

49.23%

+872.97K

2024Q1

67

14.85M

50.59%

-1.40M

2023Q4

65

14.94M

51.56%

-1.48M

2023Q3

68

15.61M

53.96%

-846.00K

2023Q2

65

15.70M

54.30%

-590.47K

2023Q1

64

16.17M

55.93%

-250.07K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Fidelity Management & Research Company LLC

7.09M

13.5%

+766.60K

+12.13%

Mar 31, 2025

Manning (Paul B.)

2.82M

5.38%

+500.00K

+21.52%

Apr 21, 2025

Acorn Capital Advisors, LLC

2.58M

4.92%

+428.26K

+19.90%

Jun 25, 2025

Baker Bros. Advisors LP

2.44M

4.64%

-544.79K

-18.27%

Mar 31, 2025

Aguilar-Cordova (Estuardo)

2.42M

4.61%

+190.92K

+8.57%

Apr 21, 2025

Aguilar (Laura K)

2.36M

4.49%

-690.05K

-22.65%

Apr 21, 2025

The Vanguard Group, Inc.

1.74M

3.31%

+396.95K

+29.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.61M

3.06%

+515.63K

+47.27%

Mar 31, 2025

BKB Growth Investments LLC

1.30M

2.48%

+750.00K

+135.44%

Apr 21, 2025

Portolan Capital Management, L.L.C.

881.18K

1.68%

+127.44K

+16.91%

Mar 31, 2025

6.310USD

Candel Therapeutics Inc

6.310

개요

회사

금융